Dear Valued Client,

Beginning with orders submitted January 22nd, 2024, 4-ANPP will be part of Axis’ 70510: Comprehensive Panel w/ Analyte Assurance™ as a screened and automatically reflexed analyte.  What this means in terms of practical application for clients is that you will no longer receive Analyte Assurance notifications regarding 4-ANPP, but rather will receive a final qualitatively confirmed result, at no additional charge, as part of the 70510: Comprehensive Panel w/ Analyte Assurance™.

In addition to this change reflected in the 70510: Comprehensive Panel w/ Analyte Assurance™, directed testing for 4-ANPP will be moved from the 13810: Designer Opioids Panel to the 40410: Fentanyl and Metabolites Order Code.

If you have any questions regarding this change please do not hesitate to contact Lab Client Support at [email protected] to connect quickly to one of our Client Support Specialists.

We look forward to serving you.

Sincerely,

Matt Zollman

Director of Operations & Product Management